Evaluation of association of mutation in ARID family of genes with outcomes in cutaneous melanoma

Authors:

George P. Souroullas1, Tolulope Adeyelu2, Andrew Elliott2, Soo J. Park3, Kevin Kim4, Ari Vanderwalde2, George Ansstas1

Key Findings:

  • Melanoma patients with ARID mutations exhibited higher prevalence of markers associated with immune checkpoint inhibitor response, including TMB-H, PD-L1 and immune-related signatures.
  • Our data also suggests improved survival outcome in patients with ARID2 mutations, although no additional OS benefit was observed with anti-PD-L1 therapy.
External Link